More recently, the long-term assessment of anti-TNF-α inhibitor treatment to subjects diagnosed with metabolic syndrome has been shown to improve fasting blood glucose and to increase adiponectin levels, confirming a role for TNF-α in obesity-related insulin resistance in humans [21]. This evidence concerns the gene TNF and metabolic syndrome.